Genmab — November 2013
-
the agency's accelerated approval program, which allows the FDA to approve a drug to treat a serious disease based on clinical data showing that the drug has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients
-
Among the 19 patients evaluable for response, overall response rate was 94%, with CR in 17 patients, partial remission in one patient and progressive disease after the second cycle in one patient; 15 out of 15 patients evaluable for minimal residual disease in the BM showed molecular remission.
-
-
Godt at Arzerra kun jagter R/R DLBLC label, for SPectrums nye stof Marqibo deler satme tæsk ud i frontline DLBLC. TJek lige de har 10 years follow up data: https://ash.confex.com/ash/2013/webprogram/Paper55944.html
-
ja nemlig. i CHOP behandling består O jo af Vincristine. Det SPPI vil er at udskifte Vincristine med deres Liposome formulation af Vincristine kaldet marqibo og derfor lave R-CHMP (Eller A-CHMP med arzerra) istedet for CHOP fordi de beviser at Marqibo er langt stærkere end normal vincristine
-
men jeg syntes alligevel det er vanvittige resultater at få ved at skifte fra normal vincristine til marqibo. Den liposome formulation giver godt nok gas.
-
Iøvrigt tester SPPI jo også Zevalin i phase III i frontline DLBLC med Z-CHOP. Men igen, det er heller ikke konkurrent til Arzerra da de jo jagter Rituxan R/R DLBLC patienter
-
Det er fedt at Jan glæder sig over at Genmab har 10 præsentationer til ASH som det højeste nogensinde
Prøv at søg på Ibrutinib. Der er 71 præsentationer alene på det produkt 
-
http://clinicaltrials.gov/ct2/show/NCT01985126?term=Daratumumab&rank=1 det går ikke hurtigt nok !
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind